1814. Comparative Rates of Nephrotoxicity in Patients Treated with Piperacillin-tazobactam and Meropenem: a Retrospective Cohort Study.
Session: Poster Abstract Session: Antibacterial Safety
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • MEM PTZ poster v2.pdf (733.6 kB)
  • Background: Studies show an increase in acute kidney injury (AKI) in patients treated with piperacillin-tazobactam (PTZ) compared to those treated with cefepime. It is not known whether meropenem (MEM) increases the risk of AKI similarly. This study evaluated the incidence of AKI in patients treated with MEM or PTZ.

    Methods: Data were collected from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust from September 2007 through October 2015. Adults without previous renal disease, who received MEM or PTZ for at least 2 days were examined. Patients were matched on severity of illness, nephrotoxin exposure, and specific comorbidities.

    Results: There were 15554 patients who met inclusion criteria, 776 received MEM and 14778 received PTZ. The MEM patients were younger (44[27-60] v 55 [42-66] years, p<0.0001), more likely to be female (54% v 44%, p<0.0001),  were slightly more ill (Charlson comorbidity index 4 [2-5.25] v 3 [1-7], p=0.003), and had higher baseline renal function (114 [79-153] v 91 [66-122] mL/min, p <0.0001). More MEM patients had cystic fibrosis (29.5% v 2.4%, p<0.0001). AKI occurred more frequently in the PTZ group (22.5% v 13.5%, p < 0.0001). The PTZ population receiving vancomycin (VAN) experienced more AKI than those receiving PTZ alone (27.5 v 11.8%, p <0.0001). MEM+VAN had higher AKI rates than MEM alone (16.4% vs 10.6%, p=0.02). Following matching, the AKI rates were 22.8% in PTZ patients compared to 13.6% in MEM patients (p<0.0001). Table 1 shows AKI rates in relation to VAN exposure. MEM+VAN was associated with an adjusted OR of 1.68 (1.1-2.6) for AKI incidence when compared to MEM alone. PTZ alone compared to MEM alone also increased the odds of AKI (aOR 1.5 [1.05-2.21]). PTZ+VAN patients had higher odds of AKI compared to MEM+VAN patients (aOR 2.19 [1.64-2.97]). Other independent predictors of AKI were baseline creatinine clearance ≥ 90 mL/min, and unknown BMI or BMI ≥30 kg/m2.

    Conclusion: PTZ with and without VAN was associated with more frequent AKI compared to MEM. The interaction of VAN and ß-lactams warrants further research.

    Table 1: AKI rates (%) stratified by group and VAN exposure

     

    Unmatched

    Matched

    MEM

    13.5

    13.6

    MEM alone

    10.6

    10.7

    MEM+VAN

    16.4

    16.4

    PTZ

    22.5

    22.8

    PTZ alone

    11.8

    14.8

    PTZ+VAN

    27.5

    30.2

                                                  

    W. Cliff Rutter, PharmD1,2 and David S. Burgess, PharmD, FCCP2, (1)University of Kentucky HealthCare, Lexington, KY, (2)University of Kentucky, College of Pharmacy, Lexington, KY

    Disclosures:

    W. C. Rutter, None

    D. S. Burgess, None

    See more of: Antibacterial Safety
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.